Polyrizon to Acquire 20% Stake in eVTOL Drone Developer Colugo

Biotechnology company Polyrizon Ltd. (Nasdaq: PLRZ) has signed a non-binding Memorandum of Understanding (MOU) to acquire up to a 20% stake in Colugo Systems, an Israeli developer of advanced Electric Vertical Take-Off and Landing (eVTOL) drones. The deal, valued at up to US $6,000,000, marks a significant strategic pivot for Polyrizon, diversifying its portfolio from its core medical focus into the high-growth Urban Air Mobility (UAM) and defense sectors. Colugo Systems is a key supplier to customers that include the Israel Defense Forces (IDF), national first responder organizations, and commercial entities.

The agreement outlines Polyrizon's intent to acquire the stake on a fully-diluted basis, with the consideration payable in either cash or company shares. This move into the Polyrizon Colugo acquisition follows another recent MOU by Polyrizon for Arrow Aviation, a private jet company, indicating a broader strategy to enter the aerospace industry. The transaction provides Colugo with significant capital to accelerate research, development, and manufacturing of its dual-use aviation tech platforms, which serve both military and civilian applications.

Colugo's Platform and Technology

Colugo Systems has established itself with proprietary technology and a portfolio of five unique patents in Adaptive Wing Technology (AWT). This technology allows its eVTOL drone systems to combine the benefits of fixed-wing aircraft, such as endurance and range, with the vertical lift capabilities of rotary-wing aircraft. This hybrid approach is central to the performance of its platforms.

The company's ARC53 eVTOL, for example, is designed for tactical and commercial missions. According to official specifications, the ARC53 features a maximum payload of 5 kg and a flight range of up to 100 km, capabilities that distinguish it from many standard commercial drones. These specifications make it suitable for a range of applications, from military intelligence, surveillance, and reconnaissance (ISR) to civilian logistics and infrastructure inspection.

Technical Comparison: Colugo ARC53

Regulatory and Market Context

Colugo operates within a highly regulated but innovative Israeli aviation environment. The Civil Aviation Authority of Israel (CAAI) oversees the integration of unmanned systems into national airspace. Colugo's domestic operations are subject to regulations such as Regulation 10916, which mandates that all drones over 200g broadcast data to a central Unmanned Traffic Management (UTM) system.

Furthermore, the company's development of larger UAM platforms is directly influenced by the Israel National Drone Initiative (INDI). This multi-year regulatory sandbox, managed by the CAAI and the Israel Innovation Authority, is designed to test heavy eVTOLs in controlled airspace, paving the way for future commercial certification and operations. The investment from Polyrizon is expected to help Colugo navigate this complex regulatory landscape and scale its technology for broader market adoption.

Strategic Diversification and Industry Trends

Polyrizon's move reflects a growing trend of non-traditional companies, particularly micro-cap firms, diversifying into the aerospace and defense sectors to capitalize on high growth potential. This trend is underscored by recent market activity, including Gaxos's acquisition of a stake in America First Defense to enter the drone-based electronic warfare market. In a similar vein, ongoing advanced talks between Veloryx and Aero Sol for a 70% stake highlight the rapid consolidation within the Israeli defense drone sector. In March 2026, the Gaxos acquisition resulted in its expansion into drone-based electronic warfare—a pattern that supports the current situation by showing a repeatable model for cross-sector investment.

For Polyrizon shareholders, the deal offers exposure to the burgeoning eVTOL market but also introduces the risk of equity dilution or a significant cash reduction of up to $6 million. Conversely, some market analysts have expressed concern, viewing the pivot from intranasal biotech to aviation as an unfocused strategy that could dilute the company's core medical mission.

What Comes Next

The current MOU is a preliminary, non-binding agreement. Both parties are now expected to conduct due diligence and negotiate a definitive agreement. According to the terms disclosed, the MOU will automatically terminate on September 30, 2026, if a definitive deal is not finalized and closed by that date. Should a definitive agreement be executed, the transaction closing is expected to occur within seven days.

Why This Matters

This intended acquisition highlights the increasing convergence of technology, defense, and civilian logistics. It demonstrates a strategic pathway for smaller, specialized tech companies to gain access to public markets and capital through partnerships with firms in unrelated sectors. For the broader aviation industry, it signals robust investor confidence in the long-term viability of dual-use eVTOL drone systems and the future of Urban Air Mobility (UAM), particularly in technologically advanced markets like Israel.

Access up-to-date commercial aviation news and airline industry developments via omniflights.com. From aircraft production to supply chains, commercial aviation manufacturing news is covered at omniflights.com/manufacturing.